<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Harlan Laboratories, Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=22785></link><description><![CDATA[Harlan Laboratories, Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 04 Apr 2026 09:45:36 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2014/07/12_740813719_20140710170517_1351966894.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Harlan Provides Expertise for Biologics and Biosimilars]]></title><link>https://www.newswire.co.kr/newsRead.php?no=760620</link><description><![CDATA[ITINGEN, Switzerland--(Business Wire/Korea Newswire)--Harlan Laboratories, Ltd. , a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS), ) business, is prepared to meet the global demand for development programs in novel biologics and biosimilars.  While the U.S. Food and Drug Administration (FDA) is slower to adopt regulations for biosi...]]></description><pubDate>Thu, 31 Jul 2014 11:00:00 +0900</pubDate></item><item><title><![CDATA[할란, 생물의약품 및 동등생물의약품에 대한 전문기술 제공]]></title><link>https://www.newswire.co.kr/newsRead.php?no=760621</link><description><![CDATA[이팅엔, 스위스--(Business Wire/뉴스와이어)--위탁연구서비스(Contract Research Services (CRS), ) 사업을 통해 일반 및 특수 독성학 서비스를 제공하는 할란 연구소(Harlan Laboratories, Ltd., )는 새로운 생물의약품(biologics) 및 동등생물의약품(biosimilars) 개발 프로그램에 대한 세계적인 수요를 충족할 준비를 마쳤다.  미국식품의약품청(U.S. Food and Drug Administration, FDA)이 유럽의약품국(European Me...]]></description><pubDate>Thu, 31 Jul 2014 11:00:00 +0900</pubDate></item><item><title><![CDATA[Harlan and Fluofarma Sign Strategic Collaboration Agreement]]></title><link>https://www.newswire.co.kr/newsRead.php?no=758114</link><description><![CDATA[ITINGEN, Switzerland--(Business Wire/Korea Newswire)--Harlan Laboratories, Ltd. , a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS, ) business, and Fluofarma , a contract research organization specializing in high content analysis, have announced a strategic partnership that will strengthen the companies’ drug discovery and translati...]]></description><pubDate>Tue, 15 Jul 2014 21:00:00 +0900</pubDate></item><item><title><![CDATA[할란, 플루오파마와 전략적 협력 협정 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=758116</link><description><![CDATA[이팅엔, 스위스--(Business Wire/뉴스와이어)--위탁연구 서비스(Contract Research Services (CRS), ) 사업을 통해 일반 및 특수 독성학 서비스를 제공하는 비공개 업체인 할란 연구소(Harlan Laboratories, Ltd., )와 하이컨텐트 분석(high content analysis) 전문의 위탁연구기관인 플루오파마(Fluofarma, )는 두 회사의 신약개발 및 중개의학(drug discovery and translational medicine services, ) 강화를 위한 전략...]]></description><pubDate>Tue, 15 Jul 2014 21:00:00 +0900</pubDate></item></channel></rss>